Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	$0.000100	0.00%	2,040
16/07/26	$0.000100	0.00%	307
15/07/26	$0.000100	0.00%	1,297
14/07/26	$0.000100	0.00%	10,457
13/07/26	$0.000100	0.00%	9,088

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 16:52:37 17/07/2026 +03			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-75.00%

24/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
19/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI

Market Cap	6.17M 5.39M 4.97M 4.58M 8.64M 594M 8.83M 59.43M 23.38M 291M 23.16M 22.65M 1B	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-71.28M -62.3M -57.48M -52.99M -99.87M -6.86B -102M -687M -270M -3.36B -268M -262M -11.57B	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	99.93%	Yield 2022 *	-	Yield 2023	-

24/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
19/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
01/03/25	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
01/03/25	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
01/03/25	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
23/12/24	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
13/11/24	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
13/11/24	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
31/10/24	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
11/05/23	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

Syros Pharmaceuticals, Inc. Stock

Stocks

SYRS

US87184Q2066

Biotechnology & Medical Research

Valuation: Syros Pharmaceuticals, Inc.

Chart: Syros Pharmaceuticals, Inc.

Latest news : Syros Pharmaceuticals, Inc.

Analysts' recommendations: Syros Pharmaceuticals, Inc.

Press Releases: Syros Pharmaceuticals, Inc.

News in other languages: Syros Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Syros Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

01/03/25	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
18/11/24	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
13/11/24	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
13/11/24	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
01/11/24	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

24/07/23	USA-Les valeurs à suivre à Wall Street (actualisé)
05/08/21	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
05/08/21	Roche signe un accord de livraison avec Syros Pharmaceuticals

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.03
3 years	0		8.17
5 years	0		56.4
10 years	0		243.75

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	22/11/2024
Karen Hunady IRC	Investor Relations Contact	-	01/10/2022
Matthew Foster PRN	Corporate Officer/Principal	-	01/03/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/24 A	Nancy Simonian	Sell	Chief Executive Officer	37,070	0.1382%
11/25/24 A	Nancy Simonian	Sell	Chief Executive Officer	134,713	0.5025%
11/19/24 A	Gerald Quirk	Sell	Chief Financial Officer	46,657	0.1740%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS, INC.	0.00%	0.00%	-99.00%	-100.00%	2.68K
LONZA GROUP AG	-1.29%	-3.11%	-0.35%	+2.64%	49.18B
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+588.97%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+61.54%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.52%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.47%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+116.45%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+15.44%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-31.23%	13.02B
Average	+0.05%	+0.02%	+47.65%	+75.53%	24.36B
Weighted average by Cap.	-0.05%	-0.18%	+79.44%	+122.31%

	2022	2023
Net sales	14.88M 13M 12M 11.06M 20.85M 1.43B 21.31M 143M 56.41M 702M 55.88M 54.66M 2.42B	9.94M 8.68M 8.01M 7.39M 13.92M 957M 14.23M 95.77M 37.67M 469M 37.31M 36.5M 1.61B
Net income	-94.65M -82.72M -76.33M -70.36M -133M -9.12B -136M -912M -359M -4.46B -355M -348M -15.37B	-165M -144M -133M -122M -231M -15.85B -236M -1.59B -624M -7.76B -618M -604M -26.72B
Net Debt	-139M -121M -112M -103M -194M -13.36B -199M -1.34B -526M -6.54B -521M -510M -22.53B	-77.45M -67.68M -62.46M -57.57M -109M -7.46B -111M -747M -294M -3.65B -291M -284M -12.58B